Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

Oncolytics Biotech® Inc. shares T.ONC are trading unchanged at $0.56.

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Awarded earlier this year, the $44M Birmingham Biotechnology Hub grant was set to support the growth of Alabama's ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...